Ra Capital Management, L.P. Crinetics Pharmaceuticals, Inc. Transaction History

Ra Capital Management, L.P.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 17, 2021	SELL	$13.3 - $17.55 $7.5 Million - $9.9 Million	-564,102 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$12.08 - $17.46 $21.3 Million - $30.8 Million	-1,764,596 Reduced 75.78%	564,102 $7.96 Million
Q2 2020 Aug 14, 2020	BUY	$13.04 - $23.23 $4.79 Million - $8.54 Million	367,489 Added 18.74%	2,328,698 $40.8 Million
Q1 2020 May 15, 2020	BUY	$11.52 - $26.46 $990,720 - $2.28 Million	86,000 Added 4.59%	1,961,209 $28.8 Million
Q4 2018 Feb 14, 2019	BUY	$22.4 - $35.39 $3.9 Million - $6.16 Million	174,192 Added 10.24%	1,875,209 $56.2 Million
Q3 2018 Nov 14, 2018	BUY	$22.66 - $36.8 $38.5 Million - $62.6 Million	1,701,017 New	1,701,017 $48.7 Million

242

79.6M

23.3K

44.3K

Ticker CRNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,752,800
Market Cap $2.98B
Description
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...

Get notified when there are updates to the investment portfolio of Ra Capital Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Ra Capital Management, L.P. with notifications on news.